Stage Redistribution following 2018 FIGO Staging for Carcinoma Cervix– A single Instituitional study.

Dr.H.Prasanna Srinivasa Rao; Dr.Sakthi Usha Devi

Volume : X, Issue : II, February - 2020

Stage Redistribution following 2018 FIGO Staging for Carcinoma Cervix– A single Instituitional study.

Dr. H. Prasanna Srinivasa Rao, Dr. Sakthi Usha Devi

Abstract :

Cancer cervix is one of the leading causes of cancer related deaths in low and middle income countries. The FIGO 2018 staging system has ought in various pathological and radiological parameters for stage classification to guide treatment–related decision–making and for better prognostication Objective: The purpose of this study is to analyse the results of stage redistribution by applying 2018 International Federation of Gynecology and Obstetrics (FIGO) staging system for cervical cancer patients in a tertiary care cancer centre. Patients & Methods: For this study, we re–staged all patients based on the FIGO 2018 staging system of patients diagnosed at our centre with carcinoma cervix from Jan 2014 to Dec 2018. Stage by stage comparison to the previous version (FIGO 2009) was done. Results: The most significant change was from stage IIB and stage IIIB to IIIC1. Upstaging occurred significantly in stage IIIB (54.1% upstaged) followed by stage IIB(33.7% upstaged). Stage IIIC1 emerged out to be the most populous stage(36.73%) followed by stage IIIB (19.36%)& IIB(14.84%). Downstaging occurred only in stage IVB ie to stage IIIC. Conclusion: The current FIGO 2018 staging system for cervical cancer appears to be useful for predicting survival in patients considering radiological and pathological variables. As per our study, majority of the cancer cervix patients fall into a single subgroup – III C1; this, in a country were already most patients present with advanced disease, will skew the data further. Stage III C1 cervical cancer is not homogenous; sub classification within stage IIIC1 may result in better prognostication.